CTCA using 256-row dual-energy CT had a median effective dose of 5.21 mSv and lifetime cancer risk up to 1025 per million in females, highlighting dose reduction but urging caution in young females.
What is the radiation dose and attributed cancer risk associated with 256-Slice CT coronary angiography?
256-slice CT coronary angiography delivers a median effective radiation dose of 5.21 mSv, carrying a higher estimated lifetime attributable risk of cancer for females compared to males, underscoring the need for careful risk-benefit analysis.
Absolute Event Rate: 0% vs 0%
The advancement of X-ray computed tomography coronary angiography (CTCA) has facilitated the acquisition of dynamic CTCA images within a single cardiac cycle, achieving a very low radiation dose while maintaining acceptable image quality. This study aimed to evaluate the radiation dose and cancer risk in patients who underwent computed tomography coronary angiography ( CTCA). The radiation data and related parameters were analyzed in 232 patients who underwent CTCA at a single hospital. Dose data were retrospectively extracted from the hospital information system using the DoseWatch software. The effective dose (E) values were determined using CT-expo 2.5 software, while the Lifetime Attributable Risk (LAR) was estimated using sex- and age-specific risk coefficients provided by the International Commission on Radiological Protection (ICRP). The reported doses in CTCA were as follows: median (interquartile range) CT dose-length product (DLP) and volume CT dose index (CTDI vol ), which were 268 mGy cm (100–492) and 2.92 mGy (1.57–20.01), respectively, while the E was 5.21 mSv (2.16–10.7). The LAR values (per 10 6 ) ranged between 58–426 and 260–1025 for male and female patients, respectively. The CTCA doses obtained using a 256-row scanner with dual-energy technology were comparable to the previously reported values, demonstrating significantly improved dose performance through the incorporation of dose reduction features of modern CT scanners. However, risk-benefit analyses should be conducted before CTCA examinations, particularly for young female patients, to mitigate the associated cancer risk.
Alsafi et al. (Sun,) reported a other. CTCA using 256-row dual-energy CT had a median effective dose of 5.21 mSv and lifetime cancer risk up to 1025 per million in females, highlighting dose reduction but urging caution in young females.